GeNeuro Announces Positive Results from Temelimab (GNbAC1) Phase 1 High-dose Clinical Trial
International Nonproprietary Name "temelimab" Assigned to GNbAC1 Temelimab’s robust safety and tolerability profile confirmed High-dose regimen fully validated by pharmacokinetic data Enables higher dos ...